ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 25, 2023 -- For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a study presented at the annual meeting of the American College of Gastroenterology, held from Oct. 20 to 25 in Vancouver, British Columbia, Canada.
Noa Krugliak Cleveland, M.D., from the University of Chicago Medicine, and colleagues performed a retrospective analysis of upadacitinib-treated patients and examined the time to treatment change and clinical remission in patients receiving IUS monitoring versus those receiving conventional management. A total of 105 patients received upadacitinib for IBD; 20 patients were included in this analysis with 30 clinical evaluations (11 IUS, 19 non-IUS).
The researchers found that the average time to treatment change was 1.1 days postinduction in IUS patients compared with 16.6 days in non-IUS patients. Treatment changes included extended induction with upadacitinib, steroid initiation, or initiation of a different treatment. Overall, five (71.4 percent) and six (75 percent) patients in the IUS and non-IUS cohorts achieved clinical remission by 26.8 and 55.3 days, respectively. In the conventional group, reasons for delay included waiting for test results or endoscopy, communication between team members, and awaiting a scheduled visit with a provider. The reason for delay in the IUS group was waiting for a visit with the referring physician.
"Disease monitoring with IUS in IBD is associated with earlier treatment changes and shorter time to remission compared to conventional approaches to disease monitoring," the authors write. "Ongoing dissemination and incorporation of IUS in the management of IBD are warranted."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
First Responders With More Debris Exposure Have Higher Risk of Early Dementia
FRIDAY, June 14, 2024 -- More severe exposure to dust or debris among World Trade Center (WTC) responders is significantly associated with a higher risk of dementia at <65...
1990 to 2019 Saw Increase in Life Expectancy in Seniors With T1DM
FRIDAY, June 14, 2024 -- From 1990 to 2019, there was an increase in life expectancy in older people with type 1 diabetes mellitus (T1DM), according to a study published online...
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy
FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.